
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (03): 255-261.DOI: 10.12114/j.issn.1007-9572.2022.0692
Special Issue: 指南/共识最新文章合辑
• Guide·Consensus·Pathway • Next Articles
Received:2022-08-29
Revised:2022-09-22
Published:2023-01-20
Online:2022-09-30
Contact:
ZHAI Zhenguo
About author:
通讯作者:
翟振国
作者简介:![]() |
| |
![]() |
| |
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0692
| 定义 | 血液动力学特征 |
|---|---|
| PH | mPAP>20 mm Hg |
| 毛细血管前PH | mPAP>20 mm Hg |
| PAWP≤15 mm Hg | |
| PVR>2 WU | |
| 孤立性毛细血管后PH | mPAP>20 mm Hg |
| PAWP>15 mm Hg | |
| PVR≤2 WU | |
| 毛细血管后和毛细血管前混合性PH | mPAP>20 mm Hg |
| PAWP>15 mm Hg | |
| PVR>2 WU | |
| ePH | 静息和运动之间的mPAP/CO斜率>3 mm Hg·L-1·min-1 |
Table 1 Hemodynamic definition of pulmonary hypertension
| 定义 | 血液动力学特征 |
|---|---|
| PH | mPAP>20 mm Hg |
| 毛细血管前PH | mPAP>20 mm Hg |
| PAWP≤15 mm Hg | |
| PVR>2 WU | |
| 孤立性毛细血管后PH | mPAP>20 mm Hg |
| PAWP>15 mm Hg | |
| PVR≤2 WU | |
| 毛细血管后和毛细血管前混合性PH | mPAP>20 mm Hg |
| PAWP>15 mm Hg | |
| PVR>2 WU | |
| ePH | 静息和运动之间的mPAP/CO斜率>3 mm Hg·L-1·min-1 |
| 分类 | 亚类 |
|---|---|
| 1.动脉性肺动脉高压(PAH) | 1.1特发性(IPAH) 1.1.1急性血管反应试验无反应者 1.1.2急性血管反应试验阳性者 1.2遗传性(HPAH) 1.3药物与毒物相关(DPAH) 1.4疾病相关 1.4.1结缔组织疾病 1.4.2 HIV感染 1.4.3门静脉高压 1.4.4先天性心脏病 1.4.5血吸虫病 1.5具有静脉/毛细血管(PVOD/PCH)受累特征的PAH 1.6新生儿持续性肺动脉高压(PPHN) |
| 2.左心疾病相关性肺动脉高压 | 2.1心力衰竭 2.1.1射血分数保留的心力衰竭 2.1.2射血分数降低或轻度降低的心力衰竭 2.2瓣膜性心脏病 2.3导致毛细血管后肺动脉高压的先天性/获得性心血管病 |
| 3.肺部疾病和/或缺氧相关性肺动脉高压 | 3.1阻塞性肺疾病或肺气肿 3.2限制性肺疾病 3.3限制性/阻塞性并存的肺疾病 3.4低通气综合征 3.5非肺部疾病导致的低氧血症(如高海拔) 3.6肺发育障碍性疾病 |
| 4.肺动脉阻塞相关肺动脉高压 | 4.1慢性血栓栓塞性肺动脉高压(CTEPH) 4.2其他肺动脉阻塞性疾病 |
| 5.未明和/或多因素相关肺动脉高压 | 5.1血液系统疾病 5.2系统性疾病 5.3代谢性疾病 5.4伴或不伴血液透析的慢性肾衰竭 5.5肺肿瘤血栓性微血管病 5.6纤维性纵隔炎 |
Table 2 Clinical classification of pulmonary hypertension
| 分类 | 亚类 |
|---|---|
| 1.动脉性肺动脉高压(PAH) | 1.1特发性(IPAH) 1.1.1急性血管反应试验无反应者 1.1.2急性血管反应试验阳性者 1.2遗传性(HPAH) 1.3药物与毒物相关(DPAH) 1.4疾病相关 1.4.1结缔组织疾病 1.4.2 HIV感染 1.4.3门静脉高压 1.4.4先天性心脏病 1.4.5血吸虫病 1.5具有静脉/毛细血管(PVOD/PCH)受累特征的PAH 1.6新生儿持续性肺动脉高压(PPHN) |
| 2.左心疾病相关性肺动脉高压 | 2.1心力衰竭 2.1.1射血分数保留的心力衰竭 2.1.2射血分数降低或轻度降低的心力衰竭 2.2瓣膜性心脏病 2.3导致毛细血管后肺动脉高压的先天性/获得性心血管病 |
| 3.肺部疾病和/或缺氧相关性肺动脉高压 | 3.1阻塞性肺疾病或肺气肿 3.2限制性肺疾病 3.3限制性/阻塞性并存的肺疾病 3.4低通气综合征 3.5非肺部疾病导致的低氧血症(如高海拔) 3.6肺发育障碍性疾病 |
| 4.肺动脉阻塞相关肺动脉高压 | 4.1慢性血栓栓塞性肺动脉高压(CTEPH) 4.2其他肺动脉阻塞性疾病 |
| 5.未明和/或多因素相关肺动脉高压 | 5.1血液系统疾病 5.2系统性疾病 5.3代谢性疾病 5.4伴或不伴血液透析的慢性肾衰竭 5.5肺肿瘤血栓性微血管病 5.6纤维性纵隔炎 |
| 预后因素 | 低危 | 中危 | 高危 |
|---|---|---|---|
| A:WHO功能分级 | Ⅰ~Ⅱ | Ⅲ | Ⅳ |
| B:6MWD | >440 m | 165~440 m | <165 m |
| C:血浆NT-proBNP/BNP水平或RAP | BNP<50 ng/L NT-proBNP<300 ng/L或RAP<8 mm Hg | BNP 50~300 ng/L NT-proBNP 300~1 400 ng/L或RAP 8~14 mm Hg | BNP>300 ng/L NT-proBNP>1 400 ng/L或RAP>14 mm Hg |
| D:CI或SvO2 | CI≥2.5 L·min-1·(m2)-1或SvO2>65% | CI 2.0~2.4 L·min-1·(m2)-1或SvO2 60%~65% | CI<2.0 L·min-1·(m2)-1或SvO2<60% |
Table 3 2021 China Guideline PAH Hazard Stratification
| 预后因素 | 低危 | 中危 | 高危 |
|---|---|---|---|
| A:WHO功能分级 | Ⅰ~Ⅱ | Ⅲ | Ⅳ |
| B:6MWD | >440 m | 165~440 m | <165 m |
| C:血浆NT-proBNP/BNP水平或RAP | BNP<50 ng/L NT-proBNP<300 ng/L或RAP<8 mm Hg | BNP 50~300 ng/L NT-proBNP 300~1 400 ng/L或RAP 8~14 mm Hg | BNP>300 ng/L NT-proBNP>1 400 ng/L或RAP>14 mm Hg |
| D:CI或SvO2 | CI≥2.5 L·min-1·(m2)-1或SvO2>65% | CI 2.0~2.4 L·min-1·(m2)-1或SvO2 60%~65% | CI<2.0 L·min-1·(m2)-1或SvO2<60% |
| 预后评估(1年死亡率) | 低危<5% | 中危5%~20% | 高危>20% |
|---|---|---|---|
| 右心衰竭的临床表现 | 无 | 无 | 有 |
| 症状进展 | 无 | 慢 | 快 |
| 晕厥 | 无 | 偶尔晕厥 | 反复晕厥 |
| WHO功能分级 | Ⅰ、Ⅱ | Ⅲ | Ⅳ |
| 6MWD | >440 m | 165~440 m | <165 m |
| 心肺运动试验 | 最大氧耗量>15 ml·min-1·kg-1(>65%预计值) 二氧化碳通气当量斜率<36 | 最大氧耗量11~15 ml·min-1·kg-1(35%~65%预计值) 二氧化碳通气当量斜率36~44 | 最大氧耗量<11 ml·min-1·kg-1(<35%预计值) 二氧化碳通气当量斜率>44 |
| 血浆BNP或血浆NT-proBNP | BNP<50 ng/L NT-proBNP<300 ng/L | BNP 50~800 ng/L NT-proBNP 300~1 100 ng/L | BNP>800 ng/L NT-proBNP>1 100 ng/L |
| 超声心动图 | 右心房面积<18 cm2 TAPSE/sPAP >0.32 mm/mm Hg 无心包积液 | 右心房面积18~26 cm2 TAPSE/sPAP 0.19~0.32 mm/mm Hg 少量心包积液 | 右心房面积>26 cm2 TAPSE/sPAP<0.19 mm/mm Hg 中等或大量心包积液 |
| cMRI | RVEF>54% SVI>40 ml/m2 RVESVI<42 ml/m2 | RVEF 37%~54% SVI 26~40 ml/m2 RVESVI 42~54 ml/m2 | RVEF<37% SVI<26 ml/m2 RVESVI>54 ml/m2 |
| 血流动力学 | RAP<8 mm Hg CI≥2.5 L·min-1·(m2)-1 SVI>38 ml/m2 SvO2>65% | RAP 8~14 mm Hg CI 2.0~2.4 L·min-1·(m2)-1 SVI 31~38 ml/m2 SvO2 60%~65% | RAP>14 mm Hg CI<2.0 L·min-1·(m2)-1 SVI<31 ml/m2 SvO2<60% |
Table 4 2022 ESC/ERS guideline PAH patient distribution,prognosis and risk (three tiered approach)
| 预后评估(1年死亡率) | 低危<5% | 中危5%~20% | 高危>20% |
|---|---|---|---|
| 右心衰竭的临床表现 | 无 | 无 | 有 |
| 症状进展 | 无 | 慢 | 快 |
| 晕厥 | 无 | 偶尔晕厥 | 反复晕厥 |
| WHO功能分级 | Ⅰ、Ⅱ | Ⅲ | Ⅳ |
| 6MWD | >440 m | 165~440 m | <165 m |
| 心肺运动试验 | 最大氧耗量>15 ml·min-1·kg-1(>65%预计值) 二氧化碳通气当量斜率<36 | 最大氧耗量11~15 ml·min-1·kg-1(35%~65%预计值) 二氧化碳通气当量斜率36~44 | 最大氧耗量<11 ml·min-1·kg-1(<35%预计值) 二氧化碳通气当量斜率>44 |
| 血浆BNP或血浆NT-proBNP | BNP<50 ng/L NT-proBNP<300 ng/L | BNP 50~800 ng/L NT-proBNP 300~1 100 ng/L | BNP>800 ng/L NT-proBNP>1 100 ng/L |
| 超声心动图 | 右心房面积<18 cm2 TAPSE/sPAP >0.32 mm/mm Hg 无心包积液 | 右心房面积18~26 cm2 TAPSE/sPAP 0.19~0.32 mm/mm Hg 少量心包积液 | 右心房面积>26 cm2 TAPSE/sPAP<0.19 mm/mm Hg 中等或大量心包积液 |
| cMRI | RVEF>54% SVI>40 ml/m2 RVESVI<42 ml/m2 | RVEF 37%~54% SVI 26~40 ml/m2 RVESVI 42~54 ml/m2 | RVEF<37% SVI<26 ml/m2 RVESVI>54 ml/m2 |
| 血流动力学 | RAP<8 mm Hg CI≥2.5 L·min-1·(m2)-1 SVI>38 ml/m2 SvO2>65% | RAP 8~14 mm Hg CI 2.0~2.4 L·min-1·(m2)-1 SVI 31~38 ml/m2 SvO2 60%~65% | RAP>14 mm Hg CI<2.0 L·min-1·(m2)-1 SVI<31 ml/m2 SvO2<60% |
| 预后因素 | 低危 | 中低危 | 中高危 | 高危 |
|---|---|---|---|---|
| 赋分值 | 1分 | 2分 | 3分 | 4分 |
| WHO功能分级 | Ⅰ、Ⅱ | — | Ⅲ | Ⅳ |
| 6MWD | >440 m | 320~440 m | 165~319 m | <165 m |
| 血浆BNP或血浆NT-proBNP | <50 ng/L <300 ng/L | 50~199 ng/L 300~649 ng/L | 200~800 ng/L 650~1 100 ng/L | >800 ng/L >1 100 ng/L |
Table 5 2022 ESC/ERS guideline:reassessment of PAH patients during follow-up (four tiered method)
| 预后因素 | 低危 | 中低危 | 中高危 | 高危 |
|---|---|---|---|---|
| 赋分值 | 1分 | 2分 | 3分 | 4分 |
| WHO功能分级 | Ⅰ、Ⅱ | — | Ⅲ | Ⅳ |
| 6MWD | >440 m | 320~440 m | 165~319 m | <165 m |
| 血浆BNP或血浆NT-proBNP | <50 ng/L <300 ng/L | 50~199 ng/L 300~649 ng/L | 200~800 ng/L 650~1 100 ng/L | >800 ng/L >1 100 ng/L |
| [1] |
中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志,2021,101 (1):11-51. DOI:10.3760/cma.j.cn112137-20201008-02778.
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [1] | ZHANG Chu, KONG Weimin, DENG Boer. Advances in Pharmacological Treatment of Recurrent or Metastatic Cervical Cancer [J]. Chinese General Practice, 2026, 29(32): 4815-4820. |
| [2] | YI Shanye, YANG Rong, LIAO Xiaoyang, ZHOU Yiheng, LIU Lidi, YANG Ziyu, BAI Jiaxin, JIA Yu, ZHANG Xin. Interpretation of the 2024 Blood Pressure Measurement and Assessment of Arterial Structure and Function: an Expert Group Position Paper [J]. Chinese General Practice, 2026, 29(32): 4690-4694. |
| [3] | WEI Baian, YU Yan, QIU Xingying, GUO Xinfeng, YANG Lihong. The Delphi Critical Appraisal Tool: Interpretation and Practical Applications [J]. Chinese General Practice, 2026, 29(32): 4700-4709. |
| [4] | KUANG Li, DING Xinxin, MA Yuanzhu. Application of Motivational Interviewing in Healthcare Provider-Patient Communication for Chronic Disease Management in Primary Care: from Principles to Practice [J]. Chinese General Practice, 2026, 29(31): 4536-4542. |
| [5] | HAN Leyang, ZHENG Huixian, TIAN Yiran, TANG Haoqing, LONG Ren, LI Daihan, LIU Xiaoyun. Measuring Integrated Services for Rural Chronic Disease Patients Based on Formative Measurement Theory [J]. Chinese General Practice, 2026, 29(31): 4543-4550. |
| [6] | LI Xiling, ZHANG Fan, YANG Xinyue, YANG Heng. Application of Exercise Snacks in Chronic Disease Management: a Scoping Review [J]. Chinese General Practice, 2026, 29(30): 4472-4479. |
| [7] | LI Lan, LIU Lidi, ZHANG Peng, LI Dongze, YANG Ziyu, CHENG Yonglang, LIAO Xiaoyang, WAN Zhi. Lifestyle Intervention-based Weight Management: an Analysis of Key Highlights from the Partial Update of the 2025 NICE Guideline Overweight and Obesity Management (NG246) [J]. Chinese General Practice, 2026, 29(30): 4353-4359. |
| [8] | GUO Zhihong, CHEN Yingying, LIU Dewu. Efficacy and Safety of Antibiotic Bone Cement Combined with Vacuum Sealing Drainage for Diabetic Foot: a Meta-analysis [J]. Chinese General Practice, 2026, 29(30): 4503-4512. |
| [9] | WANG Dunjian, CHEN Yonggang, HU Bing, ZHAO Hengyi, YANG Qing. Application of Home-based Medication Therapy Management in Contracted Patients with Diabetes and Hypertension: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(29): 4226-4231. |
| [10] | ZHANG Han, CAI Genshen, FENG Zhengwen, ZHANG Kaiyue, LIAN Dongbo, ZHANG Hua, ZHANG Jing. Evaluating the Availability of Health Services for Obesity Comorbidities under Hierarchical Diagnosis and Treatment in Beijing: a Healthcare Institution Survey Study [J]. Chinese General Practice, 2026, 29(28): 4117-4124. |
| [11] | SHEN Biyu, LU Jiahui, LI Xin, LI Huiling, LI Chunbo, FAN Panyu, FAN Fan, MA Chenhuan, WANG Guanghai. Interpretation of International Consensus on Sleep Problems in Pediatric Palliative Care: Paving the Way [J]. Chinese General Practice, 2026, 29(28): 4047-4057. |
| [12] | SHI Li, ZHOU Zhenkun, LIU Jie, PAN Guofeng. A Randomized Controlled Trial of Sinew Meridian Theory-based Combined Acupuncture and Cupping Therapy for Postmenopausal Women with Stress Urinary Incontinence [J]. Chinese General Practice, 2026, 29(28): 4141-4146. |
| [13] | LI Zhixin, LIU Xiaoyu. Practical Research on Promoting Hierarchical Diagnosis and Treatment Through Collaborative Governance of Medical Quality in Regional Medical Alliance [J]. Chinese General Practice, 2026, 29(28): 4107-4116. |
| [14] | WU Yuqiong, CHU Xiangling, HUANG Youye, SUN Li, JIANG Tian, ZHANG Qiu, HU Honglin. A Case Report and Literature Review of Hepatocyte Nuclear Factor 4α Gene Mutation Leading to Maturity-onset Diabetes of the Young [J]. Chinese General Practice, 2026, 29(27): 4011-4015. |
| [15] | FENG Yachen, LIU Lewei, XUE Jinyue, SUN Xianlin, LIU Huanzhong. Research Progress of Wearable Technology in the Diagnosis and Treatment of Mental Disorders [J]. Chinese General Practice, 2026, 29(27): 4016-4025. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||